Literature DB >> 3485404

Immunoregulatory treatment for minimal change nephrotic syndrome.

K P Mehta, U Ali, M Kutty, U Kolhatkar.   

Abstract

Immunological studies were performed in 18 children with minimal change nephrotic syndrome proved by biopsy examination during relapse and in 15 age matched controls. All 18 children showed dysfunction of cell mediated immunity as evidenced by low absolute lymphocyte count, low blastogenesis index in response to phytohaemagglutinin stimulation, and reduced skin sensitivity to dinitrochlorobenzene when compared with controls. All 18 patients had low serum IgG concentrations, while the IgA, IgM, and C3 concentrations in the serum were within normal limits. Based on the evidence of depressed cell mediated immunity, 14 patients with nephrotic syndrome were treated with an immunoregulatory drug l-tetramisole (levamisole) for a period of 20-24 weeks. Six patients went into complete remission within 4-20 weeks of treatment, a further six patients went into partial remission, while two did not respond. On follow up (six to 24 months after stopping levamisole), of the six patients who achieved complete remission, four continued to maintain the state and two relapsed after roughly six months. Of the six patients who achieved partial remission, two went into complete remission, two continued to be in partial remission, and two relapsed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485404      PMCID: PMC1777577          DOI: 10.1136/adc.61.2.153

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  Letter: Serum immunoglobulins in idiopathic minimal-change nephrotic syndrome.

Authors: 
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Immunoregulatory properties of human plasma in very low density lipoproteins.

Authors:  F V Chisari
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

3.  Interaction of synthetic 10-tyrosyl analogues of secretin with hormone receptors on pancreatic acinar cells.

Authors:  J D Gardner; T P Conlon; H C Beyerman; A Van Zon
Journal:  Gastroenterology       Date:  1977-07       Impact factor: 22.682

4.  Hyperlipoproteinaemia, cellular immunity, and nephrotic syndrome.

Authors:  J A Menchaca; S Lefkowitz
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

5.  Changes in zinc metabolism during the course of the nephrotic syndrome.

Authors:  E W Reimold
Journal:  Am J Dis Child       Date:  1980-01

6.  Studies of T lymphocyte function and inhibitory factors in minimal change nephrotic syndrome.

Authors:  S Tomizawa; S Suzuki; M Oguri; T Kuroume
Journal:  Nephron       Date:  1979       Impact factor: 2.847

7.  Impaired cell-mediated immunity in lipoid nephrosis.

Authors:  K Matsumoto; K Osakabe; M Harada; M Hatano
Journal:  Nephron       Date:  1981       Impact factor: 2.847

8.  Steroid-responsive nephrotic syndrome and allergy: immunological studies.

Authors:  S R Meadow; J K Sarsfield; D G Scott; S M Rajah
Journal:  Arch Dis Child       Date:  1981-07       Impact factor: 3.791

9.  T-cell dysfunction in minimal-change nephrotic syndrome of childhood.

Authors:  P Fodor; M T Saitúa; E Rodriguez; B González; L Schlesinger
Journal:  Am J Dis Child       Date:  1982-08

10.  Treatment of nephrotic syndrome with levamisole.

Authors:  P Tanphaichitr; D Tanphaichitr; J Sureeratanan; S Chatasingh
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

  10 in total
  6 in total

Review 1.  Modern management of nephrotic syndrome.

Authors:  K K Kher; S P Makker; M Sweet
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

2.  Immunoregulatory treatment for minimal change nephrotic syndrome.

Authors:  P F Miller
Journal:  Arch Dis Child       Date:  1986-07       Impact factor: 3.791

3.  Lymphocyte adenosine deaminase activity in children with idiopathic nephrotic syndrome.

Authors:  Om P Mishra; Jayant Ghosh; Ziledar Ali; Malay Sen; Rajniti Prasad
Journal:  Pediatr Nephrol       Date:  2005-08-13       Impact factor: 3.714

4.  Long-term effects of levamisole treatment in childhood nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Béla Iványi; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

Review 5.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

6.  Clinical efficacy of levamisole in the treatment of primary nephrosis in children.

Authors:  J G Mongeau; P O Robitaille; F Roy
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.